| Project/Area Number |
18590526
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
MURATE Takashi Nagoya University, Scbool of Health Sciences, Professor (30239537)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOZIMA Tetsuhito Nagoya University, School of Health Sciences, Research associate (40161913)
TAKAGI Akira Nagoya University, School of Health Sciences, Professor (30135371)
BANNO Yoshiko Gifu University, School of Medicine, Associate Professor (50116852)
NOZAWA Yoshinori Gifu International Institute ofBiotechoology, Head (10021362)
SUZUKI Motoshi Nagoya University, Graduate School of Medicine, Assistant professor (80236017)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥4,020,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥420,000)
Fiscal Year 2007: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2006: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | sphingosine kinase 1 / quantitative RT-PCR / myelodysplastic syndrome / acute leukemia / sphingolipid metabolites / Elecrophysiology / GDNF / MEN2 type tumor / sphingosine kinase 1 / MEN2 type tumor / myelodysplastic syndromes / RET signal / promoter analysis |
|---|
| Research Abstract |
1.Sphingolipid metabolic enzymes gene expression of myelodysplastic syndrome (MDS) and acute leukemia was measured by quantitative RT-PCR method. It was shown that sphingosine kinase 1 (SPHK1) was increased in high risk MDS and acute leukemia and that neutral sphingomyelinase 2 (NSMase2) was decreased in bone marrow samples from high risk MDS and acute leukemia Using established leukemia cell lines, further analysis was performed. It was revealed that SPHK1 message, SPHK1 protein and SPHK enzyme activity were well correlated with IC50 of anti-cancer drug, daunorubicin (DA) . Sphingolipid metabolites were measured by LC/MS-MS (liquid column chromatography followed by tandem mass spectrometry) . DA treatment modulated each sphingolipid metabolite level. There was a remarkable heterogeneity of IC50 of DA as well as SPHK expression level. With low dose of DA, DA-sensitive cell lines showed remarkable increase of ceramides as well as decrease of sphingosine 1-phosphate (S1P) compared with DA-resistant cell lines. The ratio of ceramide/S1P was changed greatly with IC50 dose of DA. Our results showed, for the first time, that sphingolipid rheostat model proposed by Spiegel, et. al. can be applied in hematological malignancies.
2.Using a GDNF (glial cell line derived neurotrophic factor) -responsive neuroblastoma cell line, TGW, we showed that SPHK1 was increased with GDNF and that the response was mediated through the GDNF receptor, RET. Mutated REF gene was recognized as the pathogenesis of MEN2 type tumors. We also proved that SPHK1 gene expression was increased in MEN2 type tumors and that increased SPHK1 gene expression was involved in its oncogenesis.
|
